Rare Disease Day – February 29
To mark #RareDiseaseDay on 29 February, our CEO Jean-Philippe Combal, spoke to pharmaphorum
Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy
PRESS RELEASE Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis
Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress
Paris, France, October 23, 2023 (GLOBE NEWSWIRE) – Vivet Therapeutics (“Vivet”), a clinical- stage biotechnology company
Vivet Therapeutics awarded with the Prix Galien MedStartup in New York
Vivet Therapeutics is very pleased and proud to have won the Prix Galien MedStartup Award for “Best Collaboration For the Developing Or Underserved Populations Worldwide”.
GATEWAY clinical trial for Wilson Disease has now its website
Wilson Disease is a rare, progressive genetic disorder that causes excess copper to be stored in the body.
VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
VTX-801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease
Gene Therapy aims to be a one-time treatment that may stop or slow the progression of Wilson disease
Learn how gene therapy aims to target the cause of Wilson disease by delivering a working ATP7B gene into cells. ClinicalTrials are now open for this investigational therapy.
Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!
Congratulations to all Women in Gene Therapy and to Dr. Gloria González-Aseguinolaza our CSO @Vivet Therapeutics!
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s PFIC Gene Therapy Programs
Mirum Pharmaceuticals and Vivet Therapeutics Enter into Exclusive Worldwide Option and License Agreement for Vivet’s Gene Therapy Programs Targeting Progressive Familial Intrahepatic Cholestasis
Vivet and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for WD
Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease
